Table 1.
Study | Country of study | Design | Location and year of evaluation | Pathogen evaluated | Study quality (GRADEa) |
Zhao et al [21] | China | Retrospective cohort study | Wuhan 2020 | SARS-CoV-2b | Low |
Pei et al [22] | China | Case-control study | Peking 2003 | SARSc | Low |
Kamming et al [23] | Canada | Experience paper | Toronto 2003 | SARS | Low |
Chee et al [24] | Singapore | Experience paper | Singapore 2003 | SARS | Low |
Tien et al [25] | Canada | Case series | Toronto 2003 | SARS | Low |
Park et al [26] | South Korea | Experience paper | Sungkyunjkwan 2015 | MERSd | Low |
Beasley et al [27] | United States | Opinion paper | Washington 2004 | Smallpox | Low |
Santos de Silva et al [28] | Brazil | Case report | Vale dos Sinos 2014 | Adenovirus | Low |
aGRADE: Grading of Recommendations, Assessment, Development, and Evaluations.
bSARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
cSARS: severe acute respiratory syndrome.
dMERS: Middle Eastern respiratory syndrome.